Rituximab and Zanubrutinib for hairy cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hairy cell leukemia or its variant.
- You need to have low blood counts, an enlarged spleen or liver, swollen lymph nodes, or symptoms like weight loss, fatigue, fever, or night sweats.
- You have had at least one prior treatment with a purine analog (such as fludarabine or cladribine) or are not healthy enough for that therapy.
- You must be in generally good health, with adequate kidney and liver function.
- You must not have taken a BTK inhibitor before, and you must avoid certain medications that could interact with the study drug.
- Women who can become pregnant and men must use effective birth control during treatment and for 90 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for people with MALT lymphoma that is advanced (stage III or IV) or has come back after local treatment. The goal is to see if this two-drug combination can shrink or control the lymphoma with fewer side effects than traditional chemotherapy.
Hear when a new Hairy Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.